|
|
Article: Treatment of severe plasmodium falciparum malaria with quinidine gluconate: discontinuation of parenteral quinine from CDC service. (Center for Disease Control)
- Article from:
- MMWR. Morbidity and Mortality Weekly Report
- Article date:
- April 12, 1991
CopyrightCOPYRIGHT 1991 U.S. Government Printing Office. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CDC has recently reviewed data on the reported incidence in the United States of Plasmodium falciparum malaria and has evaluated information on the effective management of severe life-threatening infections. As a result of this review, CDC has concluded that the drug of choice in the United States for treatment of complicated P. falciparum infections is parenteral quinidine gluconate. Therefore, effective immediately, parenteral quinine dihydrochloride will no longer be available from the CDC Drug Service.
Patients with severe malaria in the United States should be treated in intensive-care facilities where central hemodynamic and electrocardiographic ...